Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.75.

Several analysts have recently weighed in on ESPR shares. JMP Securities reiterated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target on the stock.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wasatch Advisors LP grew its holdings in shares of Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock worth $53,861,000 after purchasing an additional 1,136,245 shares during the last quarter. Geode Capital Management LLC lifted its position in Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares in the last quarter. State Street Corp grew its holdings in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after acquiring an additional 99,802 shares during the last quarter. Two Sigma Advisers LP increased its position in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after acquiring an additional 16,100 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its position in Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after acquiring an additional 1,020,243 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $1.50 on Friday. Esperion Therapeutics has a one year low of $1.47 and a one year high of $3.94. The stock has a fifty day moving average price of $1.78 and a 200 day moving average price of $2.07. The stock has a market cap of $296.77 million, a P/E ratio of -2.34 and a beta of 1.04.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.